Exclusive gBosulif launch is a modest positive for Dr Reddy's

Overview

This report is a quick note by Nomura on Dr Reddy's Laboratories. The core event is the company's launch of generic gBosulif (Bosutinib tablets) 400mg in the U.S. with 180-day exclusivity. The report views this launch as a modest positive surprise because the company had not previously disclosed its partnership with MSN.

Core views

Nomura believes that the gBosulif exclusivity period can bring quantifiable short-term incremental revenue and profit to Dr Reddy's, and support growth in North America Generics excluding gRevlimid. The report also emphasizes that as contributions from India and ex-U.S. markets increase, the quality of the company's earnings is expected to improve, thereby driving valuation multiple expansion.

Analysis framework

The report uses an event-driven and single-product earnings estimation approach, conducting scenario analysis around U.S. generic exclusivity, price erosion, market share, partnership profit sharing, and EPS contribution, and incorporates these into its assessment of FY26F revenue, FY27F profit, and valuation.

Methodology notes

• Valuation methodP/E multiple method

  24x December 2027 forecast EPS

  The INR1,600 target price is based on 24x December 2027 forecast EPS of INR66.6, with the benchmark index being the Nifty 50.

• Product contribution analysisExclusivity-period revenue and profit contribution analysis

  Price erosion, market share, profit sharing

  The report assumes 30-40% price erosion during the exclusivity period, 40% market share, and a 50% profit split with MSN, and based on this estimates the contribution to FY26F revenue and FY27F net profit.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Dr Reddy's Laboratories (REDY.NS / DRRD IN)

  Core covered stock

  Strengths

  Obtained 180-day U.S. exclusivity for gBosulif; short-term product revenue and profit contribution is clear; Buy rating and target price maintained.

  Weaknesses

  Contribution size remains limited relative to overall EPS, with FY27F EPS contribution of about 2%.

  Comparison

  Currently trading at 23x/18x FY27F/FY28F EPS, while the target price uses 24x December 2027 forecast EPS.

  Risks

  U.S. market price erosion, delays in key product approvals, adverse FX moves, tariff impacts, regulatory actions, or price controls.

• gBosulif (Bosutinib tabs) 400mg

  Event-driven product

  Strengths

  180-day U.S. exclusivity, estimated annual sales base of USD214mn, and 6% y-y volume growth.

  Weaknesses

  Price competition may intensify after the exclusivity period, and returns are affected by assumptions on price erosion and market share.

  Comparison

  Represents an incremental contribution to North America Generics growth; excluding gRevlimid, FY27F growth contribution is estimated at 2.5-3.0%.

  Risks

  Actual price erosion higher than expected, market share below expectations, or partnership profit sharing below expectations.

Key data

• gBosulif company-level annual salesUSD214mnEstimated by Nomura.
• Volume growth6% y-yIQVIA data show MAT April 2026 volume growth y-y.
• Exclusivity period180 daysLaunched by DRRD in partnership with MSN; MSN is the sole first ANDA filer for this product.
• FY26F revenue contributionUSD25-30mnBased on assumptions of 30-40% price erosion and 40% market share.
• FY27F net profit contributionUSD9-11mnAssumes a 50% profit split with MSN.
• FY27F EPS contribution ratioabout 2%Relative to Nomura's current FY27F EPS estimate of INR55.26.
• Target priceINR1,600December 2026 target price.
• Valuation multiple24xBased on December 2027 forecast EPS of INR66.6.
• Current trading valuation23x/18x FY27F/FY28F EPSCorresponding FY27F/FY28F EPS are INR55.3/INR70.4.

Impact & implications

The exclusive launch of gBosulif helps improve visibility on growth in Dr Reddy's North America generics business and provides a modest but clear EPS increment. If profit contributions from India and ex-U.S. markets continue to rise, the improvement in earnings quality could support a higher valuation.

Risks

• U.S. market price erosion may weaken returns during the gBosulif exclusivity period.
• Delays in key product approvals may affect the growth trajectory.
• Adverse FX movements, tariff impacts, regulatory actions, or price controls may hinder achievement of the target price.
• Actual product market share, profit sharing, or volume performance may fall short of assumptions.

What to watch

• Actual price erosion and market share during the gBosulif exclusivity period.
• Whether FY26F revenue contribution reaches the USD25-30mn range.
• Whether FY27F net profit contribution reaches USD9-11mn.
• Delivery of North America Generics growth excluding gRevlimid.
• Whether rising contributions from India and ex-U.S. markets can improve earnings quality and support valuation multiples.